Adial Pharmaceuticals, Inc. (ADIL) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Charlottesville, VA, 미국. 현재 CEO는 Cary John Claiborne.
ADIL 을(를) 보유 IPO 날짜 2018-07-27, 5 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $1.55M.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
